Compare · FPRX vs TRIL
FPRX vs TRIL
Side-by-side comparison of Five Prime Therapeutics, Inc. (FPRX) and Trillium Therapeutics Inc. (TRIL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FPRX and TRIL operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- TRIL carries a market cap of $1.94B.
- TRIL has more recent analyst coverage (5 ratings vs 0 for FPRX).
- Company
- Five Prime Therapeutics, Inc.
- Trillium Therapeutics Inc.
- Price
- -
- $19.30-3.45%
- Market cap
- -
- $1.94B
- 1M return
- -
- -3.79%
- 1Y return
- -
- -5.02%
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2013
- n/a
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 5
Trillium Therapeutics Inc.
Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Mississauga, Canada.
Latest FPRX
- Apexigen Announces Appointment of Francis Sarena as Chief Operating Officer
- SEC Form SC 13G/A filed by Five Prime Therapeutics, Inc. (Amendment)
- SEC Form 15-12B filed by Five Prime Therapeutics, Inc.
- SEC Form EFFECT filed by Five Prime Therapeutics, Inc.
- SEC Form 4: Sarena Francis Willard received a gift of 2,385 units of Common Stock, was granted 66,000 units of Common Stock, disposed of $6,530,414 worth of Common Stock back to the company (171,853 units at $38.00) and gifted 20,459 units of Common Stock, decreasing direct ownership by 100% to 0 units to satisfy withholding obligation
- SEC Form 4: Smith David V was granted 66,000 units of Common Stock and disposed of $5,279,986 worth of Common Stock back to the company (138,947 units at $38.00) , decreasing direct ownership by 100% to 0 units to satisfy tax liability
- SEC Form 4: Collins Helen Louise disposed of $5,150,786 worth of Common Stock back to the company (135,547 units at $38.00) , gifted 8,085 units of Common Stock and was granted 66,000 units of Common Stock, decreasing direct ownership by 100% to 0 units to satisfy tax liability
- SEC Form 4: White David disposed of $1,270,074 worth of Common Stock back to the company (33,423 units at $38.00) , decreasing direct ownership by 100% to 0 units (tax withholding)
- SEC Form 4: RINGO WILLIAM R gifted 10,000 units of Common Stock, decreasing direct ownership by 100% to 0 units
- SEC Form 4: BERGER FRANKLIN M disposed of $190,000 worth of Common Stock back to the company (5,000 units at $38.00) , decreasing direct ownership by 100% to 0 units to satisfy tax liability
Latest TRIL
- Defiance ETFs Announces Closure of Select Funds
- Defiance Launches $TRIL – The Trillion Dollar Club ETF: The New "Magnificent 7" of Global Markets
- Who's Who At The Benzinga Psychedelics Capital Conference? Check Out These CEOs & Meet Them In Person
- 10 Psychedelics CEOs To Pay Attention To In 2022
- Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of Directors
- SEC Form 15-12B filed by Trillium Therapeutics Inc.
- SEC Form EFFECT filed by Trillium Therapeutics Inc.
- SEC Form EFFECT filed by Trillium Therapeutics Inc.
- SEC Form 4: Walker Paul Edward returned 5,736,363 shares to the company
- SEC Form 4 filed by Pucci Paolo